

2024 Area of Interest for Bacterial Infections

Ceftolozane/Tazobactam:

- Retrospective clinical studies that demonstrate the effectiveness and clinical outcomes of patients treated with ceftolozane/tazobactam who were infected with extended-spectrum-beta-lactase producing Enterobacterales.
- Clinical studies describing the use of aztreonam in combination with ceftolozane/tazobactam for difficult-to-treat Gram-negative bacterial infections

Imipenem-cilastatin-relebactam (MK-7655, BLI):

- Retrospective clinical studies describing the clinical outcomes in which imipenem/cilastatin/relebactam was used to treat ceftolozane/tazobactam non-susceptible and/or ceftazidime/avibactam non-susceptible Gram-negative (GN) infections.
- Retrospective clinical studies describing the clinical outcomes of patients with polymicrobial infections treated with imipenem/cilastatin/relebactam.
- Retrospective clinical studies further describing possible nephroprotection with imipenem/cilastatin/relebactam from other nephrotoxic medications during treatment of GN infections
- Retrospective clinical studies describing the clinical outcome of patients treated with imipenem/cilastatin/relebactam for GN infections where the organisms were later found to express OXA-48 and OXA-48 like beta-lactamase.